Navigation Links
The Female Health Company to Host Third Quarter Conference Call on Friday, August 5, 2011

CHICAGO, July 29, 2011 /PRNewswire/ -- The Female Health Company (Nasdaq: FHCO) today announced that it will host an investor conference call to discuss its operating results for the third quarter and first nine months of FY2011 on Friday, August 5, 2011 at 11:00 a.m. Eastern Time (EDT).  The Company expects to report its operating results earlier the same day.

Shareholders and other interested parties may participate in the conference call by dialing 1-877-374-8416 (international participants dial 1-412-317-6716) and asking to be connected to "The Female Health Company Conference Call" a few minutes before 11:00 a.m. EDT on August 5, 2011.  A replay of the call will be available one hour after the call through 9:00 a.m. EDT on Monday, August 22, 2011 by dialing 877-344-7529 (international callers dial 412-317-0088) and entering the conference ID 10002775.  

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and about 120 other countries globally.  The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in the U.S., Europe, Canada, Australia, South Africa, Japan, Spain, Greece, Turkey and the People's Republic of China, and pending in various countries.  The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy.  The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.  

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings.  Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about The Female Health Company visit the Company's website at and If you would like to be added to the Company's e-mail alert list, please send an e-mail to .

SOURCE The Female Health Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
2. The Female Health Companys Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms
3. The Female Health Company Declares 2nd Quarter Dividend of $0.05/share
4. The Me-Covery: Saatchi & Saatchi Wellness and Time Inc.s Health Brand Reveal Historic Shift in Female Consumer Behavior
5. Co-Promotion of a New Medical Device for Female Infertility Announced
6. The Female Health Company Receives Order for 3.5 Million FC2 Female Condoms for Distribution at 2010 World Cup
7. Second-Generation Female Condom is Now Available in the United States; FC2 Female Condom Will Cost 30 Percent Less than Predecessor
8. New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence
9. Female Health Company Receives Brazilian Order: Four Million FC Female Condoms
10. New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence
11. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 USP ... hazardous drug preparations (e.g. pharmacists, pharmacy technicians, nurses, ... veterinary technicians). The chapter also covers all entities ... (e.g., pharmacies, hospitals, other healthcare institutions, patient treatment ... --> --> What ...
(Date:11/25/2015)... 25, 2015 Asia ... which BioLight and the New Investors will make a ... via a private placement. The financing will help IOPtima ... system used in the treatment of glaucoma, as well ... the IOPtimate™ system with the U.S. Food and Drug ...
(Date:11/25/2015)... LONDON , November 25, 2015 Developmental, ... key role in boosting the profitability of pharmaceutical products, ... Developmental, commercial, and regulatory/legal strategies all play ... says GBI Research . --> ... all play a key role in boosting the profitability of pharmaceutical ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 2015 , ... TyloHelo Inc , North America’s largest ... accessories help improve the bather experience in the sauna, and the accessories selected ... purist looking for simplicity in design to accessories that encourage a greater expression ...
(Date:11/25/2015)... , ... November 25, 2015 , ... For the first ... “ Two Organizations, One Beat ” campaign. The partnership between the two groups began ... aid in MAP International’s cause. , MAP International was founded in 1954 and is ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Smiles by ... TMJ Disorder, Bruxism, and moderate facial wrinkling. While many patients are aware of the ... the great success Botox® delivers to those suffering with discomfort, soreness, and pain as ...
(Date:11/25/2015)... ... ... In an ongoing Clinical Study conducted by an independent physician, Andrew Gostine, ... evaluating the efficacy of its product and its disinfection protocol. This study is taking ... 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in Chicago, ...
Breaking Medicine News(10 mins):